{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:30:17Z","timestamp":1792726217278,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100028075","name":"Promise","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ebiom.2025.105989","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:26:00Z","timestamp":1762313160000},"page":"105989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK\/PD modelling of ANCA and gammaglobulin levels in real-world patients"],"prefix":"10.1016","volume":"121","author":[{"given":"Blaise","family":"Pasquiers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-4305","authenticated-orcid":false,"given":"Benoit","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pu\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Decl\u00e8ves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Goulvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7564-6882","authenticated-orcid":false,"given":"In\u00e8s","family":"Benhabiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ternant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-4418","authenticated-orcid":false,"given":"Alicja","family":"Puszkiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2025.105989_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105989_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2023.03.004","article-title":"Treatment approaches to Granulomatosis with Polyangiitis and Microscopic polyangiitis","volume":"49","author":"Berti","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105989_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101828","article-title":"Advances in remission induction therapy for ANCA-associated vasculitis","volume":"37","author":"Morris","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105989_bib4","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105989_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ebiom.2025.105989_bib6","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-Cell\u2013Targeted therapy with Rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105989_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/acr2.11274","article-title":"Comparison of two rituximab induction regimens for Antineutrophil cytoplasm antibody\u2013associated vasculitis: systematic review and meta-analysis","volume":"3","author":"B\u00e9nard","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105989_bib8","first-page":"1","article-title":"French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)","volume":"15","author":"Terrier","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105989_bib9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105989_bib10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105989_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105989_bib12","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1111\/cts.13351","article-title":"Rituximab pediatric drug development: pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis","volume":"15","author":"Jamois","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105989_bib13","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2022-222439","article-title":"The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study","volume":"81","author":"McDermott","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105989_bib14","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, Rituximab, Hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105989_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/RHU.0000000000001688","article-title":"Defining a therapeutic window for rituximab maintenance therapy in ANCA-Associated vasculitis: a longitudinal observational Study","volume":"27","author":"Springer","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105989_bib16","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/ph14080796","article-title":"Cross-validation of a multiplex lc-ms\/ms method for assaying mabs plasma levels in patients with cancer: a gpco-unicancer study","volume":"14","author":"Marin","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105989_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40262-019-00816-7","article-title":"Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review","volume":"59","author":"Petitcollin","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"24","key":"10.1016\/j.ebiom.2025.105989_bib18","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105989_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40262-019-00826-5","article-title":"Non-Linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated vasculitis: the RAVE trial revisited","volume":"59","author":"Bensalem","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ebiom.2025.105989_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103130","article-title":"Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: a cohort study","volume":"142","author":"Liberatore","year":"2024","journal-title":"J Autoimmun"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105989_bib21","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/art.42556","article-title":"Association between Plasma Rituximab concentration and the risk of major relapse in Antineutrophil cytoplasmic antibody\u2013associated vasculitides during Rituximab maintenance therapy","volume":"75","author":"Khoudour","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105989_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/clpt.2008.235","article-title":"The use of a clinical utility index to compare insomnia compounds: a quantitative basis for benefit\u2013risk assessment","volume":"85","author":"Ouellet","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105989_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00280-013-2352-1","article-title":"Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS)","volume":"73","author":"H\u00e9nin","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105989_bib25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ebiom.2025.105989_bib26","article-title":"Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105989_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","article-title":"Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83TM, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach","volume":"81","author":"Candelaria","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105989_bib28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bcp.12098","article-title":"Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease","volume":"76","author":"Puisset","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105989_bib29","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1177\/0091270011430506","article-title":"Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia","volume":"52","author":"Li","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105989_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-016-3083-x","article-title":"Population pharmacokinetics of RedituxTM, a biosimilar Rituximab, in diffuse large B-cell lymphoma","volume":"78","author":"Gota","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105989_bib31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of Rituximab (Anti-CD20 Monoclonal Antibody) in rheumatoid arthritis patients during a phase II clinical trial","volume":"45","author":"Ng","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105989_bib32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/psp4.12885","article-title":"Rituximab pharmacokinetic and pharmacokinetic\u2013pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity","volume":"12","author":"Svensson","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ebiom.2025.105989_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116655","article-title":"A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis","volume":"175","author":"Hartinger","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105989_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-021-01081-3","article-title":"The influence of underlying disease on rituximab pharmacokinetics May be explained by target-mediated drug disposition","volume":"61","author":"Bensalem","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105989_bib35","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus","volume":"62","author":"Wincup","year":"2023","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105989_bib36","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of Antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105989_bib37","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105989_bib38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-Term rituximab use to maintain remission of Antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425004335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425004335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:00:48Z","timestamp":1763168448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425004335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"alternative-id":["S2352396425004335"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105989","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK\/PD modelling of ANCA and gammaglobulin levels in real-world patients","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105989"}}